Moberg Pharma
Develops & commercializes a leading topical treatment for nail fungus for European markets.
MOB | ST
Overview
Corporate Details
- ISIN(s):
- SE0011311596 (+3 more)
- LEI:
- 549300XFXK7DVGDRP410
- Country:
- Sweden
- Address:
- Gustavslundsvagen 42, 167 51 Stockholm
- Website:
- https://www.mobergpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Moberg Pharma is a Swedish pharmaceutical company focused on the development and commercialization of proprietary medical innovations. The company's primary asset is MOB-015, a novel topical treatment for onychomycosis (nail fungus). Marketed as Terclara®, this over-the-counter terbinafine-based product has demonstrated high fungal cure rates in Phase 3 clinical trials. Moberg Pharma has gained market approval in 13 European countries and has established Terclara® as a market leader in Sweden and Norway. The company's strategic goal is to position MOB-015 as the world's leading treatment for nail fungus, addressing a large patient population globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-11 08:00 |
Quarterly Report
|
Swedish | 783.2 KB | ||
| 2025-11-11 08:00 |
Quarterly Report
|
English | 767.1 KB | ||
| 2025-11-05 08:30 |
M&A Activity
Moberg Pharma och Karo Healthcare ingår exklusivt licensavtal för MOB-015/Tercl…
|
Swedish | 178.8 KB | ||
| 2025-11-05 08:30 |
M&A Activity
Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015…
|
English | 179.7 KB | ||
| 2025-10-31 08:30 |
Board/Management Information
Moberg Pharma’s Nomination Committee appointed
|
English | 162.2 KB | ||
| 2025-10-31 08:30 |
Board/Management Information
Moberg Pharmas valberedning utsedd
|
Swedish | 161.9 KB | ||
| 2025-10-07 08:11 |
Major Shareholding Notification
|
Swedish | 10.8 KB | ||
| 2025-09-29 14:04 |
Post-Annual General Meeting Information
Bulletin from Moberg Pharma’s Extraordinary General Meeting held on 29 Septembe…
|
English | 175.9 KB | ||
| 2025-09-29 14:04 |
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Moberg Pharma den 29 september 2025
|
Swedish | 200.1 KB | ||
| 2025-09-03 08:00 |
Pre-Annual General Meeting Information
Notice of extraordinary general meeting in Moberg Pharma AB (publ)
|
English | 181.0 KB | ||
| 2025-09-03 08:00 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)
|
Swedish | 155.9 KB | ||
| 2025-08-12 08:00 |
Interim Report
|
Swedish | 645.6 KB | ||
| 2025-08-12 08:00 |
Interim Report
|
English | 674.6 KB | ||
| 2025-07-03 16:30 |
Major Shareholding Notification
|
Swedish | 10.1 KB | ||
| 2025-07-03 10:32 |
Major Shareholding Notification
|
Swedish | 10.9 KB |
Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moberg Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moberg Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-11 | Mark Beveridge | Other | Buy | 3,000 | 17,730.00 SEK |
| 2021-11-10 | Mark Beveridge | Other | Buy | 3,000 | 17,310.00 SEK |
| 2021-11-09 | Mark Beveridge | Other | Buy | 5,000 | 29,800.00 SEK |
| 2021-02-10 | Cindy Wong | Other | Buy | 5,000 | 31,675.00 SEK |
| 2021-02-09 | Cindy Wong | Other | Buy | 5,000 | 30,800.00 SEK |
Peer Companies
